Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

Here is a look at Alzheimer’s disease, a progressive brain disorder that leads to loss of memory and other intellectual abilities. Facts Alzheimer’s disease is the most common form of dementia, which ...

Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

We maintain Eli Lilly’s High Uncertainty Rating ... including level of insurance coverage and pricing. Alzheimer’s drug donanemab holds the potential to become another major new drug, but ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Eli Lilly has been unable to secure an accelerated FDA approval for its anti-amyloid Alzheimer's disease therapy donanemab based on mid-stage clinical results, but says it remains on track to file ...

Eli Lilly and Company LLY will report its fourth ... Sales of the new Alzheimer’s drug Kisunla (donanemab) are likely to have been much higher than the third-quarter number of $1.4 million.